版本:
中国

BRIEF-Genentech says FDA advisory committee unanimously recommends approval of co’s subcutaneous rituximab for certain blood cancers

March 29 Genentech:

* FDA advisory committee unanimously recommends approval of Genentech's subcutaneous rituximab for certain blood cancers

* FDA is expected to make a decision on approval for rituximab by June 26, 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐